GE Medical's pending $9.5 billion acquisition of Amersham PLC, while cast in terms of the company's commitment to accelerate progress in personalized medicine, is fundamentally a hard-headed numbers play aimed at maintaining momentum of GE's gargantuan $10 billion medical systems business unit. GE needs healthy businesses oriented towards growing markets to maintain its momentum. And Amersham, with its stable, predictable contrast agent and protein separations businesses fits well into the portfolio. Meanwhile, the personalized medicine play holds mid-to-long term promise.
General Electric Co. 's pending $9.5
billion acquisition of Amersham PLC [See Deal], while cast in terms of the company's commitment to
accelerate progress in personalized medicine, is fundamentally a
hard-headed numbers play aimed at maintaining momentum of GE's
gargantuan $10 billion medical systems business unit.
Personalized medicine--or the application of targeted therapies to those patient populations that are most likely to respond to them (the opposite of the one-drug-fits-all approach)--is a goal in many scientific...
